ELTX is trading at $4.84 (5.8% down) in after-hours trading, extending its volatility. - The decline on July 1, 2026, comes as two law firms, Pomerantz LLP and Bronstein, Gewirtz & Grossman, LLC, announced investigations into Elicio Therapeutics on behalf of investors following the June 15 clinical trial failure of its AMPLIFY-7P study. - The company's ELI-002 7P pancreatic cancer trial failed to meet its primary endpoint, leading to a significant stock price drop on June 15, and continued market reassessment of the company's strategic options, including financing and partnerships.